Open Access

The combination of positive anti‑WDR1 antibodies with negative anti‑CFL1 antibodies in serum is a poor prognostic factor for patients with esophageal carcinoma

  • Authors:
    • Masaaki Ito
    • Satoshi Yajima
    • Takashi Suzuki
    • Yoko Oshima
    • Tatsuki Nanami
    • Makoto Sumazaki
    • Fumiaki Shiratori
    • Hao Wang
    • Liubing Hu
    • Hirotaka Takizawa
    • Shu-Yang Li
    • Yasuo Iwadate
    • Takaki Hiwasa
    • Hideaki Shimada
  • View Affiliations

  • Published online on: January 31, 2023     https://doi.org/10.3892/mi.2023.71
  • Article Number: 11
  • Copyright : © Ito et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

WD repeat‑containing protein 1 (WDR1) regulates the cofilin 1 (CFL1) activity, promotes cytoskeleton remodeling, and thus, facilitates cell migration and invasion. A previous study reported that autoantibodies against CFL1 and β‑actin were useful biomarkers for diagnosing and predicting the prognosis of patients with esophageal carcinoma. Therefore, the present study aimed to evaluate the serum levels of anti‑WDR1 antibodies (s‑WDR1‑Abs) combined with serum levels of anti‑CFL1 antibodies (s‑CFL1‑Abs) in patients with esophageal carcinoma. Serum samples obtained from 192 patients with esophageal carcinoma and other solid cancers. And s‑WDR1‑Ab and s‑CFL1‑Ab titers were analyzed using the amplified luminescent proximity homogeneous assay‑linked immunosorbent assay. Compared with those of healthy donors, the s‑WDR1‑Ab levels were significantly higher in the 192 patients with esophageal, whereas these were not significantly higher in the samples from patients with gastric, colorectal, lung, or breast cancer. In 91 patients treated with surgery, sex, tumor depth, lymph node metastasis, stage and C‑reactive protein levels were significantly associated with overall survival, as determined using the log‑rank test, whereas the squamous cell carcinoma antigen, p53 antibody and s‑WDR1‑Ab levels tended to be associated with a worse prognosis. Although no significant difference was observed in the survival between the positive and negative groups of s‑WDR1‑Abs or s‑CFL1‑Abs alone in the Kaplan‑Meier test, the patients in the s‑WDR1‑Ab‑positive and s‑CFL1‑Ab‑negative groups exhibited a significantly poorer prognosis in the overall survival analysis. On the whole, the present study demonstrates that the combination of positive anti‑WDR1 antibodies with negative anti‑CFL1 antibodies in serum may be a poor prognostic factor for patients with esophageal carcinoma.
View References

Related Articles

Copy and paste a formatted citation
x
Spandidos Publications style
Ito M, Yajima S, Suzuki T, Oshima Y, Nanami T, Sumazaki M, Shiratori F, Wang H, Hu L, Takizawa H, Takizawa H, et al: The combination of positive anti‑WDR1 antibodies with negative anti‑CFL1 antibodies in serum is a poor prognostic factor for patients with esophageal carcinoma. Med Int 3: 11, 2023.
APA
Ito, M., Yajima, S., Suzuki, T., Oshima, Y., Nanami, T., Sumazaki, M. ... Shimada, H. (2023). The combination of positive anti‑WDR1 antibodies with negative anti‑CFL1 antibodies in serum is a poor prognostic factor for patients with esophageal carcinoma. Medicine International, 3, 11. https://doi.org/10.3892/mi.2023.71
MLA
Ito, M., Yajima, S., Suzuki, T., Oshima, Y., Nanami, T., Sumazaki, M., Shiratori, F., Wang, H., Hu, L., Takizawa, H., Li, S., Iwadate, Y., Hiwasa, T., Shimada, H."The combination of positive anti‑WDR1 antibodies with negative anti‑CFL1 antibodies in serum is a poor prognostic factor for patients with esophageal carcinoma". Medicine International 3.2 (2023): 11.
Chicago
Ito, M., Yajima, S., Suzuki, T., Oshima, Y., Nanami, T., Sumazaki, M., Shiratori, F., Wang, H., Hu, L., Takizawa, H., Li, S., Iwadate, Y., Hiwasa, T., Shimada, H."The combination of positive anti‑WDR1 antibodies with negative anti‑CFL1 antibodies in serum is a poor prognostic factor for patients with esophageal carcinoma". Medicine International 3, no. 2 (2023): 11. https://doi.org/10.3892/mi.2023.71